and acquired gatekeeper resistance mutations without evidence of FGFR1-mediated hyperphosphatemia.Methods: LOXO-FG3-22001 is a multicenter, open-label, first-in-human phase 1a/b study of LOXO-435 in patients (pts) with FGFR3-altered advanced solid tumors, including metastatic UC (mUC) (NCT05614...